Q-linea AB (OSTO:QLINEA) Retained Earnings : kr-1,557.89 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Q-linea AB Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Q-linea AB's retained earnings for the quarter that ended in Mar. 2025 was kr-1,557.89 Mil.

Q-linea AB's quarterly retained earnings declined from Sep. 2024 (kr-1,462.14 Mil) to Dec. 2024 (kr-1,517.41 Mil) and declined from Dec. 2024 (kr-1,517.41 Mil) to Mar. 2025 (kr-1,557.89 Mil).

Q-linea AB's annual retained earnings declined from Dec. 2022 (kr-1,073.26 Mil) to Dec. 2023 (kr-1,298.84 Mil) and declined from Dec. 2023 (kr-1,298.84 Mil) to Dec. 2024 (kr-1,517.41 Mil).

Q-linea AB Retained Earnings Historical Data

The historical data trend for Q-linea AB's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q-linea AB Retained Earnings Chart

Q-linea AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

Get a 7-Day Free Trial

-571.19

-804.86

-1,073.26

-1,298.84

-1,517.41

Q-linea AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Retained Earnings	Get a 7-Day Free Trial															-1,355.54	-1,421.06	-1,462.14	-1,517.41	-1,557.89

Q-linea AB Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Q-linea AB (OSTO:QLINEA) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Q-linea AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Q-linea AB (OSTO:QLINEA) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

3F8:Germany

Address

Dag Hammarskjolds vag 52 A, Uppsala, SWE, SE-752 37

Website

https://www.qlinea.com

Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.

Q-linea AB Headlines

No Headlines